Why Doximity Stock Plunged Today
Key Points
Doxmity delivered mixed fourth-quarter results, with sales rising 5% and profitability declining.
Making matters worse, management forecast 2027 revenue to rise roughly 4%.
While AI monetization is yet to take hold, Doximity is succeeding in getting AI-powered products into its customers' hands.
- 10 stocks we like better than Doximity ›
Shares of the leading digital healthcare platform for medical professionals in the U.S., Doximity (NYSE: DOCS), were down 24% as of 11 a.m. ET on Thursday after the company reported underwhelming fourth-quarter earnings. Despite offering conservative Q4 guidance at its last earnings call, Doximity barely snuck past sales expectations from Wall Street and came up shy on earnings.
For the quarter, sales rose 5%, and free cash flow (FCF) increased 11%, while the full year showed increases of 13% and 19% in revenue and FCF, respectively. Perhaps the biggest disappointment from today's report was management's full-year revenue growth guidance of only 3% to 5% in 2027 -- paired with a declining adjusted EBITDA margin.
Will AI create the world's first trillionaire? Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. Continue »
As rough as Doximity's results are on the surface -- it is a core holding for me -- I don't think the company is "doomed" by any means, operationally speaking. Rather, management openly admitted that it is increasing spending on AI-powered products (which will weigh on profitability) at a time when the healthcare professional advertising market is already soft amid broader macroeconomic challenges.
Image source: Getty Images.
Vice President of Investor Relations Perry Scott Gold touched on this weakness, explaining,
I think the overarching theme is there is more uncertainty. Policy, and now macro. I think as a result, a lot of these companies, the C-suite want to retain optionality. So we are seeing some of these incremental buys are just shorter duration.
With 85% of U.S. physicians on its network and 20 of the top 20 hospitals and pharmaceutical companies as clients, Doximity's leadership isn't in danger -- but the industry slowdown will still impact them.
While AI investments will likely continue to weigh on margins, Doximity is showing some promising progress with the all-important technology, reporting that:
- nearly half of its prescribers used AI tools
- seven of the top 20 hospitals have purchased the company's clinical AI suite
- AI search and transscribe users have tripled in nine months
Doximity's valuation at 12 times forward earnings is downright cheap, but it will be essential for the company to clear the low bar it set over the coming quarters.
Should you buy stock in Doximity right now?
Before you buy stock in Doximity, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Doximity wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $472,205!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,384,459!*
Now, it’s worth noting Stock Advisor’s total average return is 999% — a market-crushing outperformance compared to 208% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of May 14, 2026.
Josh Kohn-Lindquist has positions in Doximity. The Motley Fool has positions in and recommends Doximity. The Motley Fool has a disclosure policy.
Recommended Articles
